Structural heart disease articles

Sistema EVOQUE: reemplazo tricuspídeo transcatéter, resultados al año

TAVR: High Implantation of Self-Expanding Valves Directly Impacts ECG

TAVR: High Implantation of Self-Expanding Valves Directly Impacts ECG

TAVR has been shown beneficial, especially in high risk or inoperable patients. However, there are limitations to its use, especially with self-expanding valves, which are the need for pacemaker implantation and ECG changes after procedure.  To address this matter, researchers assessed the right and left cusp overlap effect on 254 patients undergoing TAVR with self-expanding

intervencion percutanea

Tricuspid Regurgitation: Natural Progression and Prognosis

The prevalence of tricuspid regurgitation (TR) is significant; its prognosis is well known, and severe TR stages are associated with higher mortality and hospitalization for cardiac failure (CF). Seeing as valve disease tends to evolve over time, in advanced stages, we usually check on patients at specified intervals for early identification of potential hemodynamic complications

Luz roja para el TAVI en pacientes de bajo riesgo

MYVAL, a TAVR Balloon-Expandable Valve with Promising Results

TAVR has been shown beneficial over time, and with the development of new generation of prosthetic valves and implantation techniques, outcomes have been improved, reducing the incidence of leaks y and the need for definite pacemaker.  This study looked at the evolution of 100 patients with symptomatic aortic stenosis treated with Myval THV from Meril

Sistema EVOQUE: reemplazo tricuspídeo transcatéter, resultados al año

EVOQUE: Transcatheter Tricuspid Valve Replacement, One-Year Outcomes

Treating tricuspid regurgitation (TR) has gained increasing importance in interventionism. There is abundant literature on the negative natural evolution of this condition and its unfavorable prognosis, as well as the clinical challenges associated to optimal medical treatment.  Among its percutaneous treatment options, both edge-to-edge repair devices (TEER), as showed in TriValve and TRILUMINATE trials, and

New Advances in Mitral Regurgitation Devices with Promising Results

Mitral regurgitation (MR) is a frequent valvulopathy and when the optimal medical treatment at maximum tolerated doses is not enough, surgery is the first course of action. And even though edge-to-edge repair with clips has seen substantial improvement, it is currently reserved for those at high risk of surgery.  However, there is an increasing number

pacemaker marcapasos definitivo

SAFE-TAVI Study: Safety and Efficacy of the Pressure Sensor and Pacing Guidewire

Currently, we observe an increase in the number of transcatheter aortic valve replacement (TAVR) procedures due to its expansion toward a younger population with lower risk. For this reason, it is crucial to maintain continuous technological innovation to minimize post-procedural complications. The FDA has approved the SavyWire, a preformed 0.035-caliber guidewire that offers three essential

Intervención tricuspídea heterotópica: Resultados de TricValve a un año

Heterotopic Tricuspid Intervention: TricValve One-Year Outcomes

Severe tricuspid regurgitation (TR) presents a reserved prognosis when not treated in time, seeing as systemic venous congestion might significantly limit quality of life in these patients. For many years it was thought diuretic therapy was the only option to treat these patients, since the surgical alternative offered suboptimal results and many patients were deemed

La clave para tratar strokes: saber cuando detenerse

Predictors of Stroke at 30 Days and 6 Months After TAVR

While the rate of stroke has decreased since the early days of transcatheter aortic valve replacement (TAVR), it remains non-negligible, reaching up to 1%-3% at 30 days. As TAVR progressively expands to low-risk populations and younger patients, identifying risk factors for patient selection and management in stroke prevention becomes crucial. While researchers have identified predictors

¿Es frecuente el uso de IVUS para guiar la ATC?

Can Ultrasound Treat Aortic Stenosis?

Severe calcified aortic stenosis is a common condition that can currently be effectively treated with SAVR or TAVR. However, some patients, given comorbidities or anatomical characteristics, are not good candidates for these therapeutic alternatives.  The non-invasive ultrasound therapy (NIUT) has surged as viable alternative. It claims ultrasound might act on calcified valves, and mobilize tissue

ATC sobre arterias nativas o puentes venosos, ¿cuál tiene mejor pronóstico?

Is AS Only Important When Severe?

Aortic stenosis (AS) is a progressive disease associated with morbidity and mortality, especially in severe cases. However, recent studies have revealed that moderate stenosis can also have unfavorable consequences in the course of the disease. One of the challenges lies in that determining its severity is sometimes difficult due to discrepancies between valve area, gradient,

Debemos tener en cuenta a la isquemia crítica de MM II en el TAVI

Low Gradient, Normal Flow Aortic Stenosis: Changes in Quality of Life with TAVR

There is no question as regards the recommended treatment for symptomatic severe aortic stenosis, seeing as both transcatheter and surgical aortic valve replacement (TAVR and SAVR) have shown to significantly improve prognosis. This is despite the fact that there is still certain ambiguity around its characterization, which looks to define it according to hemodynamic severity

Top